ALLO Earnings Allogene Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.18 | 2026-05-13 | 10-Q |
| FY 2025 | 2025-12-31 | -0.87 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -0.70 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.51 | 2025-08-13 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.28 | 2026-05-13 | 10-Q |
| FY 2025 | 2024-12-31 | -1.32 | 2026-03-12 | 10-K |
| Q3 2025 | 2024-09-30 | -1.04 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.73 | 2025-08-13 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.38 | 2025-05-13 | 10-Q |
| FY 2024 | 2023-12-31 | -2.09 | 2025-03-13 | 10-K |
| Q3 2024 | 2023-09-30 | -1.58 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.23 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.69 | 2024-05-13 | 10-Q |
| FY 2023 | 2022-12-31 | -2.38 | 2024-03-14 | 10-K |
| FY 2023 | 2022-09-30 | -1.70 | 2024-03-14 | 10-K |
| FY 2023 | 2022-06-30 | -1.12 | 2024-03-14 | 10-K |
| FY 2023 | 2022-03-31 | -0.56 | 2024-03-14 | 10-K |
| FY 2023 | 2021-12-31 | -1.34 | 2024-03-14 | 10-K |
| Q3 2022 | 2021-09-30 | -1.35 | 2022-11-02 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.78 | 2022-08-09 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.